Katherine Bishop
Corporate Officer/Principal bei ACADIA PHARMACEUTICALS INC.
Profil
Katherine M.
Bishop is currently the Director at DTx Pharma, Inc. since 2022 and the SVP, Head-Rare Disease & External Innovation at ACADIA Pharmaceuticals, Inc. since 2021.
Previously, she worked as the Director-Preclinical Research & Development at Ceregene, Inc. from 2001 to 2009, Vice President-Clinical Development at Ionis Pharmaceuticals, Inc. from 2009 to 2015, Chief Scientific Officer at Tioga Pharmaceuticals, Inc. in 2015, Chief Scientific Officer at Otonomy, Inc. from 2017 to 2019, and Chief Scientific Officer at Locanabio, Inc. from 2019 to 2020.
Dr. Bishop holds a doctorate degree from the University of Alberta, and undergraduate degrees from the University of British Columbia and Simon Fraser University.
Aktive Positionen von Katherine Bishop
| Unternehmen | Position | Beginn |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
DTx Pharma, Inc.
 DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | Director/Board Member | 02.05.2022 |
Ehemalige bekannte Positionen von Katherine Bishop
| Unternehmen | Position | Ende |
|---|---|---|
Locanabio, Inc.
 Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.12.2020 |
| OTONOMY | Chief Tech/Sci/R&D Officer | 01.07.2019 |
Tioga Pharmaceuticals, Inc.
 Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.11.2016 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.04.2015 |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | Chief Tech/Sci/R&D Officer | 01.09.2009 |
Ausbildung von Katherine Bishop
| University of Alberta | Doctorate Degree |
| University of British Columbia | Undergraduate Degree |
| Simon Fraser University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Ceregene, Inc.
Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Ceregene, Inc. develops pharmaceutical products for neurodegenerative disorders. The company was founded in January 2001 and it is headquartered in Richmond, CA. | Health Technology |
Tioga Pharmaceuticals, Inc.
Tioga Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
DTx Pharma, Inc.
DTx Pharma, Inc. Pharmaceuticals: MajorHealth Technology DTx Pharma, Inc. engages in the provision of biotechnology solutions. It focuses on the utilization of fatty acids to enable the delivery of RNA therapeutics to tissues and organ systems beyond the liver. The company was founded by Arthur T. Suckow, John Grundy, and Adam Pavlicek in August 2017 and is headquartered in San Diego, CA. | Health Technology |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Locana, Inc. engages in the provision of ribonucleic acid targeting gene therapy. Its platform technology addresses a wide spectrum of human genetic diseases. It has advanced a powerful modular RNA targeting-effector approach to optimize and advance therapeutic candidates that is distinct from DNA-targeted approaches and nucleic acid-based RNA targeting. The company was founded by Gene Yeo and David Nelles in 2016 and is headquartered in San Diego, CA. | Technology Services |
